ERBB2 - erb-b2 receptor tyrosine kinase 2 Gene
Species: Bos taurus
Gene Type: protein coding
Gene ID: 505709
About ERBB2
Primary_assembly 19: 40,071,906-40,097,898 forward strand.ARS-UCD1.2:CM008186.2
This gene has 1 transcript (splice variant), 200 orthologues and 56 paralogues.
ERBB2 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001303629.1 | NP_001290558.1 | receptor tyrosine-protein kinase erbB-2 precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
receptor tyrosine-protein kinase erbB-2 |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(6)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-50898 | Lapatinib | 99.83% | Yes | |
| HY-13272 | Dacomitinib | 99.74% | Yes | |
| HY-50898A | Lapatinib ditosylate | 99.98% | Yes | |
| HY-50898B | Lapatinib ditosylate monohydrate | 99.99% | Yes | |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-50898C | Lapatinib tosylate | / | Unkown |
Clinical Phase
Bioactive Molecules
(13)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-10045 | AEE788 | 98.39% | Phase 2 | |
| HY-14674 | CP-724714 | 98.72% | Phase 2 | |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Phase 2 |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.54% | Phase 2 |
| HY-10322 | Falnidamol | Inhibitor | 99.41% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-135366 | HPN-01 | Inhibitor | 98.61% | Phase 1 |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Phase 1 |
Inhibitory Antibodies
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
Pre-clinical Phase
Bioactive Molecules
(51)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-112411 | PD 174265 | 98.35% | Unkown | |
| HY-13896 | PD168393 | 98.01% | Unkown | |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-20878 | Tyrphostin AG 879 | 99.26% | Unkown | |
| HY-10325 | CL-387785 | 99.31% | Unkown | |
| HY-15844 | AG-825 | 98.13% | Unkown | |
| HY-P4082 | ErbB-2-binding peptide | 99.52% | Unkown | |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-50898S | Lapatinib-d4 | 99.02% | Unkown | |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | / | Unkown | |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | ≥95.0% | Unkown | |
| HY-E70715 | ERBB2 775YVMA776 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-118900 | CP-654577 | / | Unkown | |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | / | Unkown | |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | / | Unkown | |
| HY-175809 | SRT6 | Inhibitor | / | Unkown |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | / | Unkown | |
| HY-50898S2 | Lapatinib-d5 | / | Unkown | |
| HY-50898S3 | Lapatinib-d4-1 | / | Unkown | |
| HY-50898S5 | Lapatinib-13C,d7 | / | Unkown | |
| HY-P10981 | ErbB2 peptide | Ligand | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | / | Unkown | |
| HY-RS04468 | ERBB2 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-W740576 | 7-Descarbamoyl-17-amino geldanamycin | / | Unkown | |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-10325R | CL-387785 (Standard) | / | Unkown | |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-174671 | Human HBEGF mRNA | / | Unkown | |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-50898CS | Lapatinib-d4 tosylate | / | Unkown | |
| HY-50898S4 | Lapatinib-d7 | / | Unkown |
Inhibitory Antibodies
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P990695 | Lunaxafusp | Inhibitor | / | Unkown |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |